Aims and Objectives: Robust data of ferritin are available as a prognostic marker in bacterial infection and we have analyzed its usefulness in coronavirus disease 2019 (COVID-19) pneumonia in predicting severity of illness, response to treatment, and final outcome. Materials and Methods: A multicentric, prospective, observational, and interventional study included 1000 COVID-19 cases confirmed with reverse transcription–polymerase chain reaction. All cases were assessed with lung involvement documented and categorized on high-resolution computed tomography (CT) thorax, oxygen saturation, inflammatory marker, ferritin at entry point, and follow-up during hospitalization. Age, gender, comorbidity and use of BIPAP (bilevel positive airway pressure)/NIV (non-invasive ventilation) /NIV, and outcome as with or without lung fibrosis as per CT severity were key observations. Statistical analysis was done using Chi-square test. Observations and Analysis: In a study of 1000 COVID-19 pneumonia cases, age (<50 and > 50 years) and gender (male versus female) had a significant association with ferritin (P < 0.00001 and P < 0.010, respectively). CT severity score at entry point with ferritin level had a significant correlation in severity score (P < 0.00001). Ferritin level had a significant association with duration of illness (P < 0.00001). Comorbidities had a significant association with ferritin level (P < 0.00001). Ferritin level had a significant association with oxygen saturation (P < 0.00001). BIPAP/NIV during hospitalization had a significant association with ferritin level (P < 0.00001). Timing of BIPAP/NIV requirement in critical care setting had a significant association with ferritin level (P < 0.00001). Follow-up ferritin titer during hospitalization as compared to entry point normal and abnormal ferritin had a significant association in post-COVID lung fibrosis, respectively (P < 0.00001). Conclusions: Ferritin has documented very crucial role in COVID-19 pneumonia in predicting severity of illness, progression of illness and requirement of mechanical ventilation, assessing response to treatment during hospitalization. Follow up ferritin titre during hospitalization and at discharge can be used as early predictor of post-covid lung fibrosis.

No abstract

No abstract

Introduction: Covid-19 pneumonia is heterogeneous disease with variable effect on lung parenchyma, airways and vasculature leading to long term effects on lung functions. Materials and methods: Multicentric, prospective, observational and interventional study included 1000 covid-19 cases confirmed with RT PCR. All cases were assessed with HRCT thorax, oxygen saturation, inflammatory marker as D-Dimer at entry point and follow up. Age, gender, Comorbidity and use BIPAP/NIV and outcome as with or without lung fibrosis were key observations. In selected cases, lower limb venous doppler and CT pulmonary angiography to rule out DVT or PTE. Statistical analysis is done by using Chi square test. Observations and analysis: Age (<50 and >50 years) and gender (male versus female) has significant association with D-Dimer level. [p<0.00001] & [p<0.010] respectively. CT severity score at entry point with D-Dimer level has significant correlation. [p<0.00001] D-Dimer level has significant association with duration of illness prior to hospitalization. [p<0.00001] Comorbidities have significant association with D-Dimer level. [p<0.00001] D-Dimer level has significant association with oxygen saturation. [p<0.00001] BIPAP/NIV requirement has significant association with D-Dimer level. [p<0.00001] Timing of BIPAP/NIV requirement during hospitalization has significant association with DDimer level. [p<0.00001] Follow-up D-Dimer titer during hospitalization as compared normal & abnormal to entry point level has significant association with post-covid lung fibrosis, deep vein thrombosis and pulmonary thromboembolism. [p<0.00001]. Conclusion: D-Dimer has documented very crucial role in covid-19 pneumonia in predicting severity of illness and assessing response to treatment during hospitalization and follow up titers have significant role in step-up or step-down interventions in critical care setting.

Rheumatological manifestation with acute febrile respiratory illness known to occur after coronavirus disease 2019 (COVID-19) pneumonia and presenting as long COVID disease, its occurrence with COVID vaccination is not very well associated or described in the literature. In this case report, a 45-year-old female presented with constitutional symptoms, persistent fever, and lung parenchymal infiltrates, without mycobacterial microscopic or genome documentation, received empirical antituberculosis (TB) treatment with the progression of disease with little clinical or radiological response. Bronchoscopy workup was inconclusive and tropical screen for bacterial, fungal, TB, and malignancy was negative. Vasculitis workup was inconclusive and rheumatological workup documented highly raised antinuclear antibodies titers. We have started her on steroid and hydroxychloroquine and clinical response documented with near-complete resolution of shadows in 12 weeks. Rheumatological syndrome which is a rare vaccine-related adverse event, reversible and easily treatable with routinely available medicines and importantly it is having excellent prognosis. Minimal systemic adverse events are known to occur with all viral vector vaccines, but its occurrence is rare and it should not impact on routine vaccinations as vaccination is a key step in this pandemic to protect humankind.